 |
|
 |
Diagnostics |
|
|
Therapeutic/Diagnostic Devices for Neurological Disorders
Publication Date March 2007
Publisher Business Communications Company
Product Type Report
Pages 151
ISBN Number not applicable
Product Code BCC063
|
|
|
Summary
This study examines trends in drug discovery and development for neurodegenerative disorders. Diseases examined include Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), the muscular dystrophies (MD), multiple sclerosis (MS), Parkinson's disease (PD), and Batten disease (BD) and Niemann-Pick disease (NPD), two rare disorders for which treatments exist or are in clinical trials.
It examines medications approved by regulatory agencies as well as candidate drugs in clinical trials. Sponsors range from large companies such as Wyeth to smaller ones, such as PTC Therapeutics and Amorfix. Trends in financing and business approaches are examined, as are strategies for commercializing new products. The report also makes predictions about technologies and approaches that are more or less likely to succeed, and how they are likely to grow in the next 5 years.
Scope Of Study
This report contains:
- An analysis of the trends in drug discovery and development for the neurodegenerative disorders
- An overview of the global neurological disorders treatment market which provides definitions and a structure for the industry
- Provides details for the treatment markets of specific diseases such as Alzheimer's, amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, muscular dystrophy, and other, rarer neurological disorders
- Offers a detailed analysis of patents as well as important technological developments
- A review of government regulations
- Profiles the most important companies in the industry today.
Report Highlights
- The global market for neurological disease treatment and medication was worth $12.6 billion in 2006 and will reach $14 billion by 2007. At a compound annual growth rate (CAGR) of 11.6%, the global market will be worth almost $24.3 billion by 2012.
- Drugs for multiple sclerosis, Alzheimer's disease, and Parkinson's disease control approximately 99% of the total market share.
- Medications for multiple sclerosis are just over 35% greater than the market share of medication for Alzheimer's disease, despite the fact that there are far fewer patients with MS. As AD drugs become more prevalent, the shares of the market could change dramatically.
|
Content
- Study Goals And Objectives
- Reasons For Doing The Study
- Audience For The Report
- Scope And Format
- Methodology And Information Sources
- About The Author
- Bcc Information And Related Bcc Studies
- Disclaimer
- Bcc Research Online Services
- Summary Table: Global Market Forecast For Branded Medications For Neurodegenerative Disorders, Through 2012 ($ Millions)
- Summary Figure: Global Market Forecast For Branded Medications For Neurodegenerative Disorders, 2006-2012 ($ Millions
- Government Regulations
- Introduction
- Drug Discovery
- Preclinical Testing And Submission Of An Ind
- Clinical Trials
- Timeline And Costs
- Submission Of An Nda Or Bla
- Post-Fda Approval
- New Drug Approvals
- Conclusions
- About Alzheimer's Disease
- Current Branded Pharmaceuticals That Treat Alzheimer's Disease
- Aricept (Donepezil Hcl)
- Acetylcholinesterase Inhibitors
- Generic Competition
- Cognex (Tacrine Hydrochloride)
- Ebixa, Namenda, And Axura (Memantine Hydrochloride)
- Nmda Antagonists
- Patent Protection And Second-Generation Nmda Antagonists
- Exelon (Rivastigmine Tartrate)
- Razadyne (Galantamine Hydrobromide)
- Compounds In Clinical Trials For Ad
- Alzhemed
- Flurizan
- Neramexane
- Phenserine
- Failed Ad Candidate Drugs
- Company Profiles
- Forest Laboratories
- Medivation
- Merz Pharma Gmbh & Co. Kgaa
- Neurochem, Inc.
- Sciele Pharma, Inc.
- Als: Background Information
- Rilutek: The Sole Fda-Approved Drug For Als
- Animal Models Of Als And Preclinical Studies
- Strengths Of Rodent Als Models
- Limitations Of Rodent Als Models
- Als Drug Candidates In Clinical Trials
- Current Collaborations And Drug Discovery Programs In Als Drug Discovery Or Development
- Aeolus Pharmaceuticals
- Biogen Idec And Amorfix Life Sciences
- Isis Pharmaceuticals
- Metabolon
- Power3 Medical Products
- Diagnostic Products For Als
- Company Profiles
- Aeolus Pharmaceuticals
- Amorfix Life Sciences
- Avicena Group, Inc.
- Cytrx Corp.
- Isis Pharmaceuticals, Inc.
- Metabolon
- Power3 Medical Products
- Huntington's Disease: Background Information
- Tetrabenazine Likely The First Product To Gain Fda Approval For Huntington's Disease
- Hd Drug Candidates In Clinical Trials
- Miraxion
- Dimebon
- Creatine/Hd-02
- Minocycline
- Other Agents In Clinical Trials For Hd
- Company Profiles
- Amarin Corp., Plc
- Avicena Group, Inc.
- Medivation
- Prestwick Pharmaceuticals
- About Ms
- Current Pharmaceutical Agents That Treat Multiple Sclerosis
- Avonex
- Factors Affecting Avonex Sales
- Betaseron
- Factors Affecting Sales Of Betaseron
- Generic Competition
- Cross-Border Sales In The European Union
- Tysabri
- Copaxone
- Factors Affecting Copaxone's Future Revenues
- Novantrone (Mitoxantrone)
- Rebif
- Factors Affecting Rebif's Future Revenues
- Tysabri
- Ms Drug Candidates In Clinical Trials
- Early Stage Collaborations In Ms
- Company Profiles
- Biogen Idec
- Chemocentryx, Inc.
- Paratek Pharmaceuticals
- Pdl Biopharma, Inc.
- Serono International Sa
- Syntonix Pharmaceuticals, Inc.
- Teva Pharmaceuticals
- Characteristics Of The Parkinson's Disease Therapeutics Industry
- About Parkinson's Disease
- Shortcomings Of Levodopa Therapy And New Medications
- Improvements To Levodopa Monotherapy
- Dopamine Agonists
- Anticholinergics
- Mao-B Inhibitors
- Comt Inhibitors
- Current Branded Pharmaceutical Agents That Treat Pd
- Apokyn/ Apomorphine
- Injectable Apomorphine: Barriers To Market Penetration
- Azilect (Rasagiline)
- Mirapex (Pramipexole)
- Mirapex And Compulsive Behaviors
- Mirapex And Restless Legs Syndrome
- Requip (Ropinirole Hydrochloride)
- Requip And Compulsive Behaviors
- Stalevo And Comtan
- Tasmar (Tolcapone)
- Zelapar (Selegiline Hcl)
- Pd Drug Candidates In Clinical Trials
- E2007
- Direct-To-The-Brain Drug Delivery
- Company Profiles
- Orion Pharmaceuticals
- Teva Pharmaceuticals
- Valeant Pharmaceuticals
- Vernalis, Plc
- The Muscular Dystrophies
- Background Information
- Md Drug Candidates In Clinical Trials
- Ptc124
- Stamulumab
- Other Agents In Clinical Trials For Md
- Rare Neurodegenerative Disorders
- Candidates For Rare Neurodegenerative Disorders In Clinical Trials
- Batten Disease
- Niemann-Pick Disease
- Adrenoleukodystrophy
- Lorenzo's Oil
- Company Profiles
- Genzyme
- Ptc Therapeutics
- Stem Cells, Inc.
- Wyeth Pharmaceuticals
- Introduction
- Amyotrophic Lateral Sclerosis (Als)
- General Trends
- Trends By Assignee
- Patent Application Trends
- Trends By Country
- Huntington's Disease (Hd)
- Alzheimer's Disease (Ad)
- Parkinson's Disease (Pd)
- Multiple Sclerosis (Ms)
- Muscular Dystrophy (Md)
- Trends By Assignee
- Md-Related Patent Applications
- A Rare Disorder: Ataxia-Telangiectasia
- List Of Tables
- Summary Table: Global Market Forecast For Branded Medications For Neurodegenerative Disorders, Through 2012 ($ Millions)
- Table 1 Drugs Approved By The Fda, 1993-1999
- Table 2 Drugs Approved By The Fda, 2000-2006
- Table 3 New Molecular/Biological Entities Approved By The Fda, 1980-2006
- Table 4 Nme Approvals For Neurological Disorders, 2004-2006
- Table 5 Global Market Forecast For Alzheimer's Disease Pharmaceuticals, Through 2012 ($ Millions)
- Table 6 Global Market Forecast For Aricept Sales, Through 2012 ($ Millions)
- Table 7 Global Market Forecast For Cognex Sales, Through 2012 ($ Millions)
- Table 8 Global Market Forecast For Memantine Sales, Through 2012 ($ Millions)
- Table 9 Nmda Antagonists In Clinical Trials
- Table 10 Global Market Forecast For Ad-Related Exelon Sales, Through 2012 ($ Millions)
- Table 11 Global Market Forecast For Razadyne Sales, Through 2012 ($ Millions)
- Table 12 Potential Ad Agents In Phase Iii Clinical Trials
- Table 13 Global Market Forecast For Als Therapeutics, Through 2012 ($ Millions)
- Table 14 U.S. Market Forecast For Rilutek, Through 2012 ($ Millions)
- Table 15 Als/Sod1 Rodent Models
- Table 16 A Sample Of Als Drug Candidates In Clinical Trials
- Table 17 Als Drug Candidates For Which Ndas Have Been Filed With The Fda
- Table 18 Als Drug Candidates That Peformed Well In Clinical Trials
- Table 19 A Sample Of Recent Als Drug Candidates That Did Not Peform Well In Clinical Trials
- Table 20 Als Drug Candidates In Preclinical Development
- Table 21 U.S. Marketforecast For Als Diagnostic Products, Through 2012 ($ Millions)
- Table 22 Research Efforts Aimed At Biomarkers For Als
- Table 23 Global Market Forecast For Huntington's Disease Therapeutic Agents, Through 2012 ($ Millions)
- Table 24 Global Market Forecast For The U.S. And Worldwide Sales For Tetrabenazine, Through 2012 ($ Millions)
- Table 25 Hd Drug Candidates In Clinical Trials
- Table 26 Global Market Forecast For Multiple Sclerosis Therapeutics, Through 2012 ($ Millions)
- Table 27 Overall Market Leaders In Ms Therapeutic Agents, 2005 And 2006 ($ Millions)
- Table 28 U.S. Market Leaders In Ms Therapeutics, 2006 And 2006 ($ Millions)
- Table 29 Global Market Forecast For Avonex Sales, Through 2012 ($ Millions)
- Table 30 U.S. Avonex Sales As A Percentage Of Total Sales, 2003-2012 (Percent (%) Rounded To The Nearest Whole Value)
- Table 31 Global Market Forecast For Betaseron, Through 2012 ($ Millions)
- Table 32 U.S. Betaseron Sales As A Percentage Of Total Sales, 2003-2012 (Rounded To The Nearest Whole Value)
- Table 33 Global Market Forecast For Copaxone, Through 2012 ($ Millions)
- Table 34 U.S. Copaxone Sales As A Percentage Of Total Sales, 2003-2012 (Percent (%) Rounded To The Nearest Whole Value)
- Table 35 Global Market Forecast For Brand-Name Novantrone, Through 2012 ($ Millions)
- Table 36 Global Market Forecast For Rebif, Through 2012 ($ Millions)
- Table 37 U.S. Rebif Sales As A Percentage Of Total Sales, 2003-2012 (Percent (%) Rounded To The Nearest Whole Value)
- Table 38 Global Market Forecast For Tysabri, Through 2012 ($ Millions)
- Table 39 A Sample Of Ms Drug Candidates In Clinical Trials
- Table 40 Global Market Forecast For Parkinson's Disease Therapeutics, Through 2012 ($ Millions)
- Table 41 Global Market Forecast For Apokyn/Apomorphine, Through 2012 ($ Millions)
- Table 42 Global Market Forecast For Azilect, Through 2012 ($ Millions)
- Table 43 Global Market Forecast For Mirapex, Through 2012 ($ Millions)
- Table 44 Global Market Forecast For Requip For Parkinson's Disease, Through 2012 ($ Millions)
- Table 45 U.S. Pd-Releated Requip Sales As A Percentage Of Total Sales, 2004-2012 (Percent (%) Rounded To The Nearest Whole Value)
- Table 46 Global Market Forecast For Comtan/Stalevo, Through 2012 ($ Millions)
- Table 47 Global Market Forecast For Tasmar, Through 2012 ($ Millions)
- Table 48 Global Market Forecast For Zelapar, Through 2012 ($ Millions)
- Table 49 A Sample Of Pd Drug Candidates In Clinical Trials
- Table 50 Global Market Forecast For Muscular Dystrophy-Related Therapeutic Agents, Through 2011 ($ Millions)
- Table 51 Md Drug Candidates In Clinical Trials
- Table 52 Global Market Forecast For Rare Neurodegenerative Disorders, Through 2012 ($ Millions)
- Table 53 Candidates In Clinical Trials For Rare Disorders
- Table 54 Als-Related Technology: U.S. Patent Trends, 1997-2007*
- Table 55 Als-Related Patents By Use Category
- Table 56 Als-Related Patents By Assignee Category
- Table 57 Als-Related Patents By Company
- Table 58 Als-Related Patent Applications By Use Category
- Table 59 Als-Related Technology: U.S. Patent Application Trends, 2001-2006
- Table 60 Huntington's Disease-Related Technology: U.S. Patent Trends, 1997-2007
- Table 61 Hd-Related Patents By Use Category
- Table 62 Hd-Related Patents By Assignee Category
- Table 63 Hd-Related Patents By Company
- Table 64 Alzheimer's Disease-Related Technology: U.S. Patent Trends, 1997-2007
- Table 65 Ad-Related Patents By Use Category
- Table 66 Ad-Related Patents By Assignee Category
- Table 67 Ad-Related Patents By Company
- Table 68 Parkinson's Disease-Related Technology: U.S. Patent Trends, 1997-2007
- Table 69 Pd-Related Patents By Use Category
- Table 70 Pd-Related Patents By Assignee Category
- Table 71 Pd-Related Patents By Company
- Table 72 Multiple Sclerosis-Related Technology: U.S. Patent Trends, 1997-2007
- Table 73 Ms-Related Patents By Use Category
- Table 74 Ms-Related Patents By Assignee Category
- Table 75 Ms-Related Patents By Company
- Table 76 Muscular Dystrophy-Related Technology: U.S. Patent Trends, 1997-2007
- Table 77 Md-Related Patents By Use Category
- Table 78 Md-Related Patents By Assignee Category
- Table 79 Md-Related Patents By Organization
- Table 80 Muscular Dystrophy-Related Technology: U.S. Patent Application Trends, 2001-2007
- Table 81 Md-Related Patent Applications By Use Category
- Table 82 Rare Disorder Patent Applications By Disease
- Table 83 Ataxia-Telangiectasia-Related Patents By Use Category
- List Of Figures
- Summary Figure: Global Market Forecast For Branded Medications For Neurodegenerative Disorders, 2006-2012 ($ Millions)
- Figure 1 Global Market Forecast For Alzheimer's Disease Pharmaceuticals, 2005-2012 ($ Millions)
- Figure 2 Global Market Forecast For Als Therapeutics, 2005-2012 ($ Millions)
- Figure 3 Global Market Forecast For Huntington's Disease Therapeutic Agents, 2006-2012 ($ Millions)
- Figure 4 Global Market Forecast For Multiple Sclerosis Therapeutics, 2005-2012 ($ Millions)
- Figure 5 Global Market Forecast For Parkinson's Disease Therapeutics, 2005-2012 ($ Millions)
- Figure 6 Global Market Forecast For Muscular Dystrophy-Related Therapeutic Agents, 2005- 2021 ($ Millions)
- Figure 7 Global Market Forecast For Rare Neurodegenerative Disorders, 2005-2012 ($ Millions)
|
|
|
